The rotenone model of Parkinson's disease: Genes, environment and mitochondria

Parkinsonism and Related Disorders

Volumn 9, Issue SUPPL. 2, 2003, Pages 59-64

  Greenamyre, J Timothy ^a   Betarbet, Ranjita ^a   Sherer, Todd B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lewy bodies; Parkinson's disease; Pathogenesis

Indexed keywords

PESTICIDE; ROTENONE; TOXIN;

BRAIN MITOCHONDRION; CONFERENCE PAPER; DISEASE MODEL; DOPAMINERGIC SYSTEM; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0042160300     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(03)00023-3     Document Type: Conference Paper

References (68)

1. Wooten G.F. Neurochemistry and neuropharmacology of Parkinson's disease. Watts R.L., Koller W. Movement Disorders: Neurologic Principles and Practice. 1997;153-160 McGraw-Hill, New York.
2. Forno L.S., Langston J.W. Lewy bodies and aging: relation to Alzheimer's and Parkinson's diseases. Neurodegeneration. 2:1993;19-24.
3. Pollanen M.S., Dickson D.W., Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol. 52:1993;183-191.
4. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 388:1997;839-840.
5. Trojanowski J.Q., Lee V.M. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol. 55:1998;151-152.
6. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 18:1966;925-964.
7. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 20:1973;415-455.
8. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem. 69:1997;1326-1329.
9. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol. 31:1992;119-130.
10. Cleeter M.W., Cooper J.M., Schapira A.H. Irreversible inhibition of mitochondrial complex I by 1-methyl-4- phenylpyridinium: evidence for free radical involvement. J Neurochem. 58:1992;786-789.
11. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 36:1994;348-355.
12. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA. 93:1996;2696-2701.
13. Bindoff L.A., Birch-Machin M., Cartlidge N.E., Parker W.D. Jr., Turnbull D.M. Mitochondrial function in Parkinson's disease. Lancet. 2:1989;49.
14. Blin O., Desnuelle C., Rascol O., Borg M., Peyro Saint Paul H., Azulay J.P., Bille F., Figarella D., Coulom F., Pellissier J.F., et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J Neurol Sci. 125:1994;95-101.
15. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun. 163:1989;1450-1455.
16. Parker W.D. Jr., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 26:1989;719-723.
17. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1:1989;1269.
18. McNaught K.S., Olanow C.W., Halliwell B., Isacson O., Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci. 2:2001;589-594.
19. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1988;1285-1291.
20. Hirsch E.C., Hunot S., Damier P., Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol. 44:1998;S115-S120.
21. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 46:1999;598-605.
22. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
23. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:1998;605-608.
24. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
25. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
26. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 4:1998;1318-1320.
27. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine- alpha-synuclein adduct. Science. 294:2001;1346-1349.
28. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha- synuclein nitration in synucleinopathy lesions. Science. 290:2000;985-989.
29. Paxinou E., Chen Q., Weisse M., Giasson B.I., Norris E.H., Rueter S.M., Trojanowski J.Q., Lee V.M., Ischiropoulos H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci. 21:2001;8053-8061.
30. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 293:2001;263-269.
31. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 25:2000;302-305.
32. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA. 97:2000;13354-13359.
33. Liu Y., Fallon L., Lashuel H.A., Liu Z., Lansbury P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 111:2002;209-218.
34. Hertzman C., Wiens M., Bowering D., Snow B., Calne D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am J Ind Med. 17:1990;349-355.
35. Kirkey K.L., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Gorell J.M. Occupational categories at risk for Parkinson's disease. Am J Ind Med. 39:2001;564-571.
36. Le Couteur D.G., McLean A.J., Taylor M.C., Woodham B.L., Board P.G. Pesticides and Parkinson's disease. Biomed Pharmacother. 53:1999;122-130.
37. McCann S.J., LeCouteur D.G., Green A.C., Brayne C., Johnson A.G., Chan D., McManus M.E., Pond S.M. The epidemiology of Parkinson's disease in an Australian population. Neuroepidemiology. 17:1998;310-317.
38. Priyadarshi A., Khuder S.A., Schaub E.A., Shrivastava S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology. 21:2000;435-440.
39. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., Richardson R.J. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology. 20:1999;239-247.
40. Racette B.A., McGee-Minnich L., Moerlein S.M., Mink J.W., Videen T.O., Perlmutter J.S. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology. 56:2001;8-13.
41. Gavin C.E., Gunter K.K., Gunter T.E. Manganese and calcium transport in mitochondria: implications for manganese toxicity. Neurotoxicology. 20:1999;445-453.
42. Hollingworth R.M., Ahammadsahib K.I., Gadelhak G., McLaughlin J.L. New inhibitors of complex I of the mitochondrial electron transport chain with activity as pesticides. Biochem Soc Trans. 22:1994;230-233.
43. Vingerhoets F.J., Snow B.J., Tetrud J.W., Langston J.W., Schulzer M., Calne D.B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol. 36:1994;765-770.
44. Farrer M., Maraganore D.M., Lockhart P., Singleton A., Lesnick T.G., de Andrade M., West A., de Silva R., Hardy J., Hernandez D. Alpha-synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet. 10:2001;1847-1851.
45. Menegon A., Board P.G., Blackburn A.C., Mellick G.D., Le Couteur D.G. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet. 352:1998;1344-1346.
46. Schapira A.H., Gu M., Taanman J.W., Tabrizi S.J., Seaton T., Cleeter M., Cooper J.M. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol. 44:1998;S89-S98.
47. Furuno T., Landi M.T., Ceroni M., Caporaso N., Bernucci I., Nappi G., Martignoni E., Schaeffeler E., Eichelbaum M., Schwab M., Zanger U.M. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics. 12:2002;529-534.
48. Langston J.W. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology. 47:1996;S153-S160.
49. Langston J.W., Irwin I., Langston E.B. Pargyline prevents MPTP-induced Parkinsonism in primates. Science. 225:1984;1480-1482.
50. + by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol. 106:1984;455-456.
51. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4- phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
52. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun. 163:1989;1450-1455.
53. Schapira A.H.V., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1:1989;1269.
54. Benecke R., Strumper P., Weiss H. Electron transfer complex I defect in idiopathic dystonia. Ann Neurol. 32:1992;683-686.
55. Haas R.H., Nasirian F., Nakano K., Ward D., Pay M., Hill R., Shults C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol. 37:1995;714-722.
56. Gu M., Cooper J.M., Taanman J.W., Schapira A.H. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol. 44:1998;177-186.
57. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett J.P. Jr., Davis R.E., Parker W.D. Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol. 40:1996;663-671.
58. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys Acta. 1364:1998;222-235.
59. 3H]dihydrorotenone. J Neurochem. 75:2000;2611-2621.
60. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 3:2000;1301-1306.
61. Davey G.P., Clark J.B. Threshold effects and control of oxidative phosphorylation in nonsynaptic rat brain mitochondria. J Neurochem. 66:1996;1617-1624.
62. 3H]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study. J Neurosci. 16:1996;3807-3816.
63. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 22:2002;7006-7015.
64. Hensley K., Pye Q.N., Maidt M.L., Stewart C.A., Robinson K.A., Jaffrey F., Floyd R.A. Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J Neurochem. 71:1998;2549-2557.
65. Gao H.M., Hong J.S., Zhang W., Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci. 22:2002;782-790.
66. Lee H.J., Shin S.Y., Choi C., Lee Y.H., Lee S.J. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem. 277:2002;5411-5417.
67. Lee H.J., Choi C., Lee S.J. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem. 277:2002;671-678.
68. Betarbet R., Sherer T.B., Kim J.-H., Baptista M., Cookson M.R., Greenamyre J.T. Rotenone models of Parkinson's disease: altered α-synuclein expression following chronic inhibition of complex I. 2002;Society for Neuroscience, Washington, DC.